Page 2428 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 148 Peripheral Artery Disease 2167.e1

REFERENCES 12. Kumbhani DJ, Steg PG, Cannon CP, et al: Statin therapy and long-term
adverse limb outcomes in patients with peripheral artery disease: insights
1. Gerhard-Herman MD, Gornik HL, Barrett C, et al: 2016 AHA/ACC from the REACH registry. Eur Heart J 35(41):2864–2872, 2014.
guideline on the management of patients with lower extremity peripheral 13. Bonaca MP, Scirica BM, Creager MA, et al: Vorapaxar in patients with
artery disease: executive summary. J Am Coll Cardiol 69:1465–1508, peripheral artery disease: results from TRA2˚P-TIMI 50. Circulation
2017. 127(14):1522–1529, 1529e1–1529e6, 2013.
1a. Hirsch AT, Haskal ZJ, Hertzer NR, et al: ACC/AHA 2005 Practice 14. Fowkes FG, Murray GD, Butcher I, et al: Ankle brachial index com-
guidelines for the management of patients with peripheral arterial bined with Framingham risk score to predict cardiovascular events and
disease (lower extremity, renal, mesenteric, and abdominal aortic): a mortality: a meta-analysis. JAMA 300:197, 2008.
collaborative report from the American Association for Vascular Surgery/ 15. Cacoub PP, Abola MT, Baumgartner I, et al: Cardiovascular risk factor
Society for Vascular Surgery, Society for Cardiovascular Angiography control and outcomes in peripheral artery disease patients in the Reduc-
and Interventions, Society for Vascular Medicine and Biology, Society tion of Atherothrombosis for Continued Health (REACH) Registry.
of Interventional Radiology, and the ACC/AHA Task Force on Practice Atherosclerosis 204:e86, 2009.
Guidelines (Writing Committee to Develop Guidelines for the Manage- 16. Stone NJ, Robinson JG, Lichtenstein AH, et al: 2013 ACC/AHA
ment of Patients with Peripheral Arterial Disease): endorsed by the guideline on the treatment of blood cholesterol to reduce atheroscle-
American Association of Cardiovascular and Pulmonary Rehabilitation; rotic cardiovascular risk in adults: a report of the American College of
National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Cardiology/American Heart Association Task Force on Practice Guide-
Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. lines. J Am Coll Cardiol 63:2889–2934, 2014. Erratum in: Circulation
Circulation 113:e463, 2006. 129(25 Suppl 2):S46, 2014.
2. Norgren L, Hiatt WR, Dormandy JA, et al: Inter-society consensus for 17. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al:
the management of peripheral arterial disease (TASC II). J Vasc Surg Effects of extended-release niacin with laropiprant in high-risk patients.
45:S5, 2007. N Engl J Med 371(3):203–212, 2014.
2a. Mozaffarian D, Benjamin EJ, Go AS, et al: Heart disease and stroke 18. Berger JS, Krantz MJ, Kittelson JM, et al: Aspirin for the prevention
statistics—2016 update: a report from the American Heart Association. of cardiovascular events in patients with peripheral artery disease: a
Circulation 133:e38–e360, 2016. meta-analysis of randomized trials. JAMA 301:1909, 2009.
3. Tendera M, Aboyans V, Bartelink ML, et al: ESC guidelines on the 19. Belch J, MacCuish A, Campbell I, et al: The prevention of progression
diagnosis and treatment of peripheral artery diseases: document covering of arterial disease and diabetes (POPADAD) trial: factorial randomised
atherosclerotic disease of extracranial carotid and vertebral, mesenteric, placebo controlled trial of aspirin and antioxidants in patients with
renal, upper and lower extremity arteries. The Task Force on the Diagno- diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840,
sis and Treatment of Peripheral Artery Diseases of the European Society 2008.
of Cardiology (ESC). Eur Heart J 32:2851–2906, 2011. 20. Fowkes FG, Price JF, Stewart MC, et al: Aspirin for prevention of
4. Anderson JL, Halperin JL, Albert NM, et al: Management of patients cardiovascular events in a general population screened for a low ankle
with peripheral artery disease (Compilation of 2005 and 2011 ACCF/ brachial index: a randomized controlled trial. JAMA 303:841, 2010.
AHA Guideline Recommendations): a report of the American College 20a. Hiatt WR, Fowkes FGR, Heizer G, et al: Ticagrelor versus clopidogrel
of Cardiology Foundation/American Heart Association Task Force on in symptomatic peripheral artery disease. N Engl J Med 376:32, 2017.
Practice Guidelines. J Am Coll Cardiol 6:1555–1570, 2013. 20b. Bonaca MP, Bhatt DL, Storey RF, et al: Ticagrelor for prevention of
5. Pande RL, Perlstein TS, Beckman JA, et al: Secondary prevention and ischemic events after myocardial infarction in patients with peripheral
mortality in peripheral artery disease: National Health and Nutrition artery disease. J Am Coll Cardiol 67:2719, 2016.
Examination study, 1999 to 2004. Circulation 124:17, 2011. 21. Gardner AW, Parker DE, Montgomery PS, et al: Efficacy of quantified
6. Fowkes FG, Rudan D, Rudan I, et al: Comparison of global estimates of home-based exercise and supervised exercise in patients with intermit-
prevalence and risk factors for peripheral artery disease in 2000 and 2010: tent claudication: a randomized controlled trial. Circulation 123:491,
a systematic review and analysis. Lancet 382(9901):1329–1340, 2013. 2011.
7. Hirsch AT, Criqui MH, Treat-Jacobson D, et al: Peripheral arterial 22. McDermott MM, Liu K, Guralnik JM, et al: Home-based walking
disease detection, awareness, and treatment in primary care. JAMA exercise intervention in peripheral artery disease: a randomized clinical
286:1317, 2001. trial. JAMA 310(1):57–65, 2013.
8. Pande RL, Creager MA: Socioeconomic inequality and peripheral artery 23. Murphy TP, Cutlip DE, Regensteiner JG, et al: Supervised exercise versus
disease prevalence in US adults. Circ Cardiovasc Qual Outcomes 7(4): primary stenting for claudication resulting from aortoiliac peripheral
532–539, 2014. artery disease: six-month outcomes from the Claudication: Exercise
9. Aboyans V, Criqui MH, Abraham P, et al: Measurement and interpreta- Versus Endoluminal Revascularization (CLEVER) study. Circulation
tion of the ankle-brachial index: a scientific statement from the American 125:130, 2012.
Heart Association. Circulation 126(24):2890–2909, 2012. 23a. Fakhry F, Spronk S, van der Laan L, et al: Endovascular revascularization
9a. Marso SP, Bain SC, Consoli A, et al: Semaglutide and cardiovascular and supervised exercise for peripheral artery disease and intermittent
outcomes in patients with type 2 diabetes. N Engl J Med 375:1834, 2016. claudication: a randomized clinical trial. JAMA 314:1936, 2015.
9b. Marso SP, Daniels GH, Brown-Frandsen K, et al: Liraglutide and 23b. Shishehbor MH: Endovascular treatment of femoropopliteal lesions: so
cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311, 2016. many options, little consensus. J Am Coll Cardiol 66:2339, 2015.
9c. Zinman B, Wanner C, Lachin JM, et al: Empagliflozin, cardiovascular 23c. Rosenfield K, Jaff MR, White CJ, et al: Trial of a paclitaxel-coated
outcomes, and mortality in type 2 diabetes. N Engl J Med 374:1094, balloon for femoropopliteal artery disease. N Engl J Med 373:145, 2015.
2016. 24. Thukkani AK, Kinlay S: Endovascular intervention for peripheral artery
9d. Palmer SC, Mavridis D, Nicolucci A, et al: Comparison of clinical disease. Circ Res 116(9):1599–1613, 2015.
outcomes and adverse events associated with glucose-lowering drugs in 25. Dake MD, Ansel GM, Jaff MR, et al: Paclitaxel-eluting stents show
patients with type 2 diabetes: a meta-analysis. JAMA 316:313, 2016. superiority to balloon angioplasty and bare metal stents in femoropop-
10. Rooke TW, Hirsch AT, Misra S, et al: 2011 ACCF/AHA Focused update liteal disease: twelve-month Zilver Ptx randomized study results. Circ
of the guideline for the management of patients with peripheral artery Cardiovasc Interv 4:495, 2011.
disease (updating the 2005 guideline): a report of the American College 26. Fleisher LA, Beckman JA, Brown KA, et al: ACC/AHA 2006 guideline
of Cardiology Foundation/American Heart Association Task Force on update on perioperative cardiovascular evaluation for noncardiac surgery:
Practice Guidelines. Circulation 124:2020, 2011. focused update on perioperative beta-blocker therapy: a report of the
11. Collins R, Burch J, Cranny G, et al: Duplex ultrasonography, magnetic American College of Cardiology/American Heart Association Task
resonance angiography, and computed tomography angiography for Force on Practice Guidelines (Writing Committee to Update the 2002
diagnosis and assessment of symptomatic, lower limb peripheral arterial Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac
disease: systematic review. BMJ 334(7606):1257, 2007. Surgery): developed in Collaboration with the American Society of